Search: WFRF:(Fransson Göran) >
Cost-effectiveness ...
Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy
-
- Aspelin, P. (author)
- Karolinska Institutet
-
- Aubry, P. (author)
- Department of Cardiology, Ctr. Hosp. Universitaire Bichat, Paris, France
-
- Fransson, Sven Göran (author)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Institutionen för medicin och vård,Kardiologiska kliniken
-
show more...
-
- Strasser, R. (author)
- Department of Cardiology, Heart Center, University of Technology, Dresden, Germany
-
- Willenbrock, R. (author)
- Department of Cardiology, Hospital St. Elisabeth, Halle, Germany
-
- Lundkvist, J. (author)
- Karolinska Institutet
-
show less...
-
Karolinska Institutet Department of Cardiology, Ctr Hosp. Universitaire Bichat, Paris, France (creator_code:org_t)
- Elsevier BV, 2005
- 2005
- English.
-
In: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 149:2, s. 298-303
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background: Acute renal failure after contrast-induced nephropathy is a clinically important and costly complication after the use of iodine-based contrast media. We investigated the cost and cost-effectiveness of 2 contrast media in patients at high risk of contrast-induced nephropathy. Methods: The analyses were based on a randomized, prospective, multinational clinical study comparing the nephrotoxic effects of an isosmolar nonionic contrast medium, iodixanol, with those of a low-osmolar nonionic contrast medium, iohexol. Resource utilization data were obtained from the study and from a retrospective review of patients' hospital records. Swedish, German, and French unit prices were applied to resources used. Between-group differences in average costs were analyzed using a nonparametric bootstrap method. Results: Resource utilization data for 125 patients were analyzed. Seven contrast media-related serious adverse reactions, of which 6 were acute renal failures, were noted in 6 patients receiving iohexol. Two patients in the iodixanol group had 1 nonserious reaction each. The mean hospitalization cost per patient was €489, €573, and €393 lower after iodixanol than after iohexol using Swedish, German, and French unit prices, respectively. The mean per-patient costs of treating adverse drug reactions were €371, €399, and €445 lower after iodixanol than after iohexol, using the respective unit prices (P = 0.01). Iodixanol was cost-effective compared with iohexol, with both lower costs and better effects related to fewer adverse drug reactions. Conclusions: The isosmolar contrast medium iodixanol appears to be cost-effective when compared with a low-osmolar contrast medium, iohexol, in diabetic patients with renal impairment undergoing angiography. © 2005, Elsevier Inc. All rights reserved.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
To the university's database